Feb 3, 2021
An Interview with Dr. Ian Smith, Founder, Director and Chief Medical Officer of Panthera Biopartners and CEO of Panthera Biopartners Stuart Young discussing the Lessons from Covid-19 and the differing strategies for recruiting and retaining patients in oncology and chronic diseases including CNS, Rheumatoid arthritis, Nash and cardiovascular.
About Panthera:
An independent site management organization run by a world-class
team of experts, finds patients and runs clinical trials on behalf
of CROs and pharma companies across multiple therapeutic areas.
https://www.panthera-bio.com/
About Dr. Ian Smith:
Dr. Ian founded Synexus, the world’s first independent clinical
trials organization, whilst practicing as a GP. He went on to build
the Synexus model into the foremost SMO with sites across the
world.
Today Ian is a non-executive director of several healthcare companies. Ian was awarded an MBE for services to health research.
About CEO Stuart Young
Stuart previously managed the UK division of Synexus overseeing
nine dedicated research sites. Stuart is particularly focused on
the use of technology to reduce costs in clinical trials, provide a
first rate patient experience and ensure that Panthera is at the
cutting edge of clinical research.
Stuart, holds a degree in Mechanical Engineering from University of Strathclyde in Glasgow, has had extensive experience in data management and the introduction of new technologies into organizations.